Viveve Launches GENEVEVE™ by Viveve Treatment in Canada

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s health and wellness, today announced the launch of direct sales of the GENEVEVE treatment to physicians and healthcare providers in Canada. Delivered by the internationally patented Viveve® System, the GENEVEVE treatment improves sexual function by treating the vaginal introitus, after vaginal childbirth.

“We are excited to offer Canadian physicians and patients Viveve’s clinically proven cryogen cooled monopolar radiofrequency technology for the treatment of vaginal laxity, a common medical condition experienced by millions of women, that impacts their sexual satisfaction and quality of life,” said Patricia Scheller, chief executive officer of Viveve.  “Women now have options and they no longer need to just accept bothersome symptoms.  This safe, sound, and comfortable treatment provides women and their doctors an innovative therapeutic solution, backed by rigorous clinical science,” she continued.

Educational materials and informational sessions that address the value and clinically proven benefits of the GENEVEVE treatment are available throughout Canada for healthcare providers, and their female patients. Additional information and the calendar of key physician events are available at



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.